Meta-analysis and gene set enrichment relative to ER status reveal elevated activity of MYC and E2F in the "Basal" breast cancer subgroup

PLoS ONE

Volumn 4, Issue 3, 2009, Pages

  Alles, M Chehani ^a   Gardiner Garden, Margaret ^a   Nott, David J ^b   Wang, Yixin ^c   Foekens, John A ^d   Sutherland, Robert L ^a   Musgrove, Elizabeth A ^a   Ormandy, Christopher J ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c JOHNSON AND JOHNSON   (United States)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MYC PROTEIN; TRANSCRIPTION FACTOR E2F; MYC PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPLICATION; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HORMONE RESPONSE; HUMAN; HUMAN CELL; PROTEIN INTERACTION; TRANSCRIPTION REGULATION; ALGORITHM; BASAL CELL CARCINOMA; BREAST TUMOR; COMPUTER ASSISTED DIAGNOSIS; DNA MICROARRAY; FEMALE; GENETICS; META ANALYSIS; METABOLISM; PHYSIOLOGY; REGULATORY SEQUENCE;

ALGORITHMS; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; DIAGNOSIS, COMPUTER-ASSISTED; E2F TRANSCRIPTION FACTORS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ESTROGEN; REGULATORY ELEMENTS, TRANSCRIPTIONAL; TUMOR MARKERS, BIOLOGICAL;

EID: 62749199200     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004710     Document Type: Article

References (54)

1. Sims AH, Howell A, Howell SJ, Clarke RB (2007) Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol 4: 516-525.
2. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
3. Gruvberger SK, Ringner M, Chen Y, Panavally S, Saal LH, et al. (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61: 5979-5984.
4. Abba MC, Hu Y, Sun H, Drake JA, Gaddis S, et al. (2005) Gene expression signature of estrogen receptor alpha status in breast cancer. BMC Genomics 6: 37.
5. Schneider J, Ruschhaupt M, Buness A, Asslaber M, Regitnig P, et al. (2006) Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer. International Journal of Cancer 119: 2974-2979.
6. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization and Integrated Discovery. Genome Biology 4: R60.
7. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. PNAS 102: 15545-15550.
8. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, et al. (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24: 4660-4671.
9. Miller LD, Smeds J, George J, Vega VB, Vergara L, et al. (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102: 13550-13555.
10. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.
11. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
12. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
13. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, et al. (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121-132.
14. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
15. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-R964.
16. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression pattern of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98: 10869-10874.
17. Choi JK, Yu U, Kim S, Yoo OJ (2003) Combining multiple microarray studies and modeling interstudy variation. Bioinformatics 19: i84-i90.
18. Lusa L, Gentleman R, Ruschhaupt M (2006) GeneMeta: MetaAnalysis for High Throughput Experiments. R package version 140.
19. Benjamini Y, Yekutieli D (2001) The control of the false discovery rate in multiple testing under dependency. Ann Statist 29: 1165-1188.
20. Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR (2002) GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nature Genetics 31: 19-20.
21. R website: www.R-package.org.
22. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
23. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 38: 1289-1297.
24. Musgrove EA, Sergio CM, Loi S, Inman CK, Anderson LR, et al. (2008) Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer. PLoS ONE 3: e2987.
25. Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, eds. 'Bioinformatics and Computational Biology Solutions using R and Bioconductor'. New York: Springer. pp Chapter 23.
26. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, et al. (2005) Systematic discovery of regulatory motifs in human promoters and 3 [prime] UTRs by comparison of several mammals. Nature 434: 338-345.
27. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL (1998) c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Molecular and Cellular Biology 18: 4499-4508.
28. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
29. Jones C, Ford E, Gillett C, Ryder K, Merrett S, et al. (2004) Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes. Clin Cancer Res 10: 5988-5997.
30. Wang ZC, Lin M, Wei LJ, Li C, Miron A, et al. (2004) Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 64: 64-71.
31. Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, et al. (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes, Chromosomes and Cancer 45: 1033-1040.
32. Creighton CJ, Cordero KE, Larios JM, Miller RS, Johnson MD, et al. (2006) Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol 7: R28.
33. Zeller KI, Zhao X, Lee CWH, Chiu KP, Yao F, et al. (2006) Global mapping of c-Myc binding sites and target gene networks in human B cells. PNAS 103: 17834-17839.
34. Rowland BD, Bernards R (2006) Re-Evaluating Cell-Cycle Regulation by E2Fs. Cell 127: 871-874.
35. Vernell R, Helin K, Muller H (2003) Identification of Target Genes of the p16INK4A-pRB-E2F Pathway. J Biol Chem 278: 46124-46137.
36. Black EP, Hallstrom T, Dressman HK, West M, Nevins JR (2005) Distinctions in the specificity of E2F function revealed by gene expression signatures. Proceedings of the National Academy of Sciences 102: 15948-15953.
37. Balciunaite E, Spektor A, Lents NH, Cam H, te Riele H, et al. (2005) Pocket Protein Complexes Are Recruited to Distinct Targets in Quiescent and Proliferating Cells. Mol Cell Biol 25: 8166-8178.
38. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, et al. (2002) E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev 16: 245-256.
39. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, et al. (2006) Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: Gene expression analyses across three different platforms. BMC Genomics 7: 127.
40. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, et al. (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49: 22-34.
41. Lin CY, Strom A, Vinsensius BV, Kong SL, Yeo AL, et al. (2004) Discovery of estrogen receptor α target genes and response elements in breast tumor cells. Genome Biology 5: R66.61-R66.17.
42. Cunliffe HE, Ringner M, Bilke S, Walker RL, Cheung JM, et al. (2003) The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. Cancer Res 63: 7158-7166.
43. McNeil CM, Sergio CM, Anderson LR, Inman CK, Eggleton SA, et al. (2006) c-Myc overexpression and endocrine resistance in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 102: 147-155.
44. Naidu R, Wahab NA, Yadav M, Kutty MK (2002) Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med 9: 189-196.
45. Cuny M, Kramar A, Courjal F, Johannsdottir V, Iacopetta B, et al. (2000) Relating Genotype and Phenotype in Breast Cancer: An Analysis of the Prognostic Significance of Amplification at Eight Different Genes or Loci and of p53 Mutations. Cancer Res 60: 1077-1083.
46. Rodriguez-Pinilla SM, Jones RL, Lambros MB, Arriola E, Savage K, et al. (2006) MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol 60: 1017-1023.
47. Blancato J, Singh B, Liu A, Liao DJ, Dickson RB (2004) Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer 90: 1612-1619.
48. Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, et al. (2007) Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9: 443-454.
49. Adem C, Soderberg CL, Hafner K, Reynolds CA, Slezak JM, et al. (2004) ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes, Chromosomes and Cancer 41: 1-11.
50. Efstratiadis A, Szabolcs M, Klinakis A (2007) Notch, Myc and Breast Cancer. Cell Cycle 6: 421-432.
51. Leone G, Sears R, Huang E, Rempel R, Nuckolls F, et al. (2001) Myc Requires Distinct E2F Activities to Induce S Phase and Apoptosis. Molecular Cell 8: 105-113.
52. Ogawa H, Ishiguro K-I, Gaubatz S, Livingston DM, Nakatani Y (2002) A Complex with Chromatin Modifiers That Occupies E2F- and Myc-Responsive Genes in G0 Cells. Science 296: 1132-1136.
53. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, et al. (2007) Gene expression profiling and histopathological characterization of triplenegative/basal-like breast carcinomas. Breast Cancer Res 9: R65.
54. Yu D, Cozma D, Park A, Thomas-Tikhonenko A (2005) Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. Ann N Y Acad Sci 1059: 145-159.